← FDA DRUG APPROVALS

FDA ANDA · ANDA212868

ATROPINE SULFATE

Sponsor: ACCORD HLTHCARE

APPLICATION
ANDA212868
TYPE
ANDA
ORIGINAL APPROVAL
2021-07-26
LATEST ACTION
2026-03-18
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ATROPINE SULFATEPrescription
ATROPINE SULFATE 0.5MG/5ML (0.1MG/ML) · SOLUTION · INTRAVENOUS
ATROPINE SULFATEPrescription
ATROPINE SULFATE 1MG/10ML (0.1MG/ML) · SOLUTION · INTRAVENOUS
ATROPINE SULFATEPrescription
ATROPINE SULFATE 0.25MG/5ML (0.05MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2026-03-18Labeling · Supplement 5 · standardAP
2023-04-07Labeling · Supplement 3 · standardAP
2022-11-23Manufacturing (CMC) · Supplement 2 · standardAP
2021-07-26UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →